stemazole

Stemazole is a **novel small molecule drug candidate** discovered via high-throughput screening for its capacity to protect and regulate stem cells[1]. It has shown significant **neuroprotective and anti-apoptotic effects**, demonstrated both in vitro and in animal models of neurodegenerative diseases—including Alzheimer's disease, Parkinson's disease, and multiple sclerosis[1][3]. Mechanistically, stemazole exerts its effects primarily by modulating apoptosis-related signaling pathways, especially the **mitogen-activated protein kinase (MAPK) pathway**, and targets including RAC-alpha serine/threonine-protein kinase (AKT1), caspase-3 (CASP3), caspase-8 (CASP8), mitogen-activated protein kinase 8 (MAPK8), and mitogen-activated protein kinase 14 (MAPK14)[1]. Stemazole has high **oral bioavailability**, can cross the blood–brain barrier, and accumulates stably in the brain[1]. It promotes oligodendrocyte precursor cell survival and remyelination, outperforming positive control drugs in experimental models of demyelinating disease[3]. It is currently positioned as a therapeutic agent for neurodegenerative and demyelinating disorders with a unique mechanism focusing on cellular protection and repair.

Brand names

stemazole

Other names

stemazole